AGENDA | MARCH 11
1:00 - 1:15 PM
Welcome and Dry Eye Overview
Presented By:
Paul Karpecki, OD, FAAO, Associate Professor - UPike College of Optometry/Kentucky Eye Institute
1:15 - 1:25 PM
Dry Eye Market - Insights From Rx
Presented By:
Donald Fishbein, President - Evolve Therapeutics, LLC
Arun Subramaniam, Senior National Accounts Director - Symphony Health
1:25 - 2:25 PM
Company Showcase
Oyster Point Pharma | Jeffrey Nau, PhD - President & CEO
Aerie Pharmaceuticals | David Hollander, MD, MBA - Chief R&D Officer
Aldeyra Therapeutics | Todd Brady - President & CEO
Allotex | Michael Mrochen - Co-Founder & President
Hovione Scientia Limited | Courtney Smith - Director of Business Development & Licensing
Mitotech S.A. | Natalia Perekhvatova - CEO
AdOM | Stan Miele - Chief Business Officer
Olympic Ophthalmics | Steve Ferguson, OD - Dunes Eye Consultants
2:25 - 3:15 PM
The Dry Eye Outlook Panel - Clinical Perspective
Panelists:
Ana Alzaga Fernandez, MD, Assistant Professor of Ophthalmology - Weill Cornell Medicine
Paul Karpecki, OD, FAAO, Associate Professor - UPike College of Optometry/Kentucky Eye Institute
Cynthia Matossian, MD, FACS, Founder and Medical Director, Matossian Eye Associates /President - American College of Eye Surgeons / VP - NY IOL Implant Society / Director of Development - WIO
Laura Periman, MD, Founder & Director, Dry Eye Services and Clinical Research - Periman Eye Institute
Yuna Rapoport, MD, MPH, Director - Manhattan Eye
Rahul S. Tonk, MD, MBA, Assistant Professor of Clinical Ophthalmology & Medical Director - Bascom Palmer Eye Institute
Moderated By:
Ashley Brissette, MD, MSc, FRCSC, Assistant Professor of Ophthalmology, Weill Cornell Medicine - New York Presbyterian Hospital
3:15 - 4:00 PM
The Dry Eye Outlook Panel - Industry Perspective
Panelists:
Doug Faunce, PhD, Executive Director, Search and Evaluation, Eye Care & Corporate Strategy - Allergan, an AbbVie company
Mark Hagler, SVP, Head of Ophthalmics, Oncology & LTC - Sun Pharma
Rob Kissling, MD, VP, Medical Affairs - Bausch + Lomb
Sajjad Roshanali, Global Head, Ocular Surface - Johnson & Johnson Vision
Jehan Tamboowalla, Head of New Ophthalmic Products - Novartis
Moderated By:
Paul Karpecki, OD, FAAO, Associate Professor - UPike College of Optometry/Kentucky Eye Institute
4:00 - 5:00 PM
Virtual Networking
PROUDLY SPONSORED BY:
Gold Sponsor
Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, is one of the world's best-known and most respected health care brands, solely focused on protecting, enhancing and restoring people's eyesight.
Silver Sponsors
Allergan
Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics.
Novartis
Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.
Bronze Sponsors
Aldeyra
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
Johnson & Johnson Vision
At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health. Through our operating companies, we've developed solutions for every stage of life-to help people see better, connect better and live better. We partner with eye care professionals to provide some of the world's leading products and technologies to address refractive error, cataracts, dry eye, and beyond. We are committed to using our reach and size for good and strive to put quality eye care within reach of everyone, everywhere.
Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).
Sun Ophthalmics
Sun Ophthalmics is reenergizing eye care. We are a US division of Sun Pharma, a global specialty pharmaceutical corporation with operations in over 150 countries. Our mission is to launch innovative ophthalmic products that complement your approach to treatment. We focus on your unmet treatment needs in patient care so you can focus on your patients. Discover a brighter future in eye care. For more information on our products and vision, visit www.SunOphthalmics.com.
MEDIA PARTNERS:
